Latest Regulatory Filings News

WA Kaolin Limited has responded to ASX queries clarifying that its Q2 FY2026 order book was a demand snapshot, not a sales forecast, and confirmed timely disclosure of a production shortfall linked to plant issues. The company also addressed regulatory notices, affirming no material impact on operations or securities value.

Immutep Limited has voluntarily suspended trading of its shares on the ASX pending the release of a key announcement regarding the interim futility analysis of its TACTI-004 Phase III trial. The suspension underscores the market’s anticipation of potentially pivotal clinical trial results.

Dimerix Limited has completed dosing of the last adult patient in its ACTION3 Phase 3 trial for DMX-200, exceeding its recruitment target and setting the stage for key regulatory milestones.

Tetratherix Limited has raised approximately $5 million to fast-track its Tutelix prostate spacer into pivotal clinical trials across Australia and the US, aiming to improve radiation therapy for prostate cancer patients.

Clarity Pharmaceuticals has completed enrolment in its Phase III AMPLIFY trial for the Cu-SAR-bisPSMA imaging agent, advancing its bid for FDA approval in prostate cancer diagnostics.

Viking Mines has successfully identified multiple new high-priority tungsten targets at its Linka Project in Nevada through cutting-edge gravity and magnetic surveys, prompting an expanded exploration program.

Greenwing Resources has updated its Que River Project scoping study, reflecting a sharp rise in metals prices that boosts projected cash flows to nearly double previous estimates. The company is advancing regulatory approvals and exploring strategic partnerships to capitalise on these improved economics.

Beetaloo Energy has responded to ASX concerns over a delayed disclosure of a director's change in interest, attributing it to an administrative oversight and pledging enhanced compliance measures.

LTR Pharma has finalised recruitment for its Phase II clinical trial of SPONTAN, a rapid-acting intranasal spray for erectile dysfunction, with initial results expected in the second quarter of 2026.

Bio-Gene Technology Limited reports strong progress in toxicology studies for Flavocide, targeting its first regulatory submission in Australia by March 2027. This milestone sets the stage for global registrations of the novel insecticide with a new mode of action.

Sequoia Financial Group has agreed with ASIC to withdraw a previously lodged Revocation Deed, signaling a regulatory shift that investors will want to watch closely.

Avecho Biotechnology has completed recruitment for the interim analysis cohort of its pivotal Phase III trial for a CBD insomnia treatment, with results expected in June 2026. This milestone could significantly de-risk the program and unlock major market opportunities.